replication protein A2 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored RPA2P3 profile across patient tissues and cancer cell-line models. RPA2P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPA2P3 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, RPA2P3 RNA expression shows 9,223 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where RPA2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPA2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPA2P3 survival associations across molecular data types. RPA2P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPA2P3 RNA expression–survival associations across cancer types. High RPA2P3 expression shows unfavorable associations in MESO, COAD, SKCM, ACC and UCEC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RPA2P3 RNA expression.
This table summarizes RPA2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPA2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPA2P3 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD and LUSC. The HNSC box plot shows higher RPA2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .002).
This table shows molecular features associated with RPA2P3 in patient tissues and cancer cell lines. In patient samples, RPA2P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
